Increasing levels of chronic subclinical inflammatory markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6), are thought to be involved in the development of T2DM via insulin resistance onset and insulin secretion disruption [143,144,145]. The gene discussed is INS; the disease is type 2 diabetes mellitus.